Real-World Healthcare Resource Use Associated with Recurrent or Metastatic Head and Neck Cancer Patients Care in Portugal-TRACE Study

被引:0
|
作者
Teixeira, Maria Margarida [1 ]
Dias, Joao [2 ]
Andre, Teresa [3 ]
Joaquim, Ana [4 ]
Fernandes, Ricardo [5 ]
Magalhaes, Joana [6 ]
Marreiros, Laura [7 ]
Pinto, Leonor [8 ]
Ribeiro, Leonor [9 ]
Nogueira, Mafalda [10 ]
Morais, Catarina [10 ]
机构
[1] Inst Portugues Oncol Coimbra Francisco Gentil, P-3000075 Coimbra, Portugal
[2] Inst Portugues Oncol Porto Francisco Gentil, P-4200072 Porto, Portugal
[3] Hosp Dr Nelio Mendonca, P-9000177 Funchal, Portugal
[4] Unidade Local Saude Gaia Espinho, P-4434502 Vila Nova De Gaia, Portugal
[5] Unidade Local Saude Braga, P-4710243 Braga, Portugal
[6] Unidade Local Saude Algarve, P-8000386 Faro, Portugal
[7] Unidade Local Saude Almada Seixal, P-2805267 Almada, Portugal
[8] Unidade Local Saude Coimbra, P-3004561 Coimbra, Portugal
[9] Unidade Local Saude Santa Maria, P-1649035 Lisbon, Portugal
[10] MSD Portugal, Paco De Arcos, Portugal
关键词
head and neck; recurrent or metastatic disease; real-world; healthcare resources; patient management; SQUAMOUS-CELL CARCINOMA; GUIDELINES(R) INSIGHTS HEAD; RECURRENT/METASTATIC HEAD; PEMBROLIZUMAB; CHEMOTHERAPY; EPIDEMIOLOGY; KEYNOTE-048; CETUXIMAB; RISK;
D O I
10.3390/curroncol31080318
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Recurrent or metastatic head and neck squamous cell carcinoma (R/M HNSCC) is a challenging disease, requiring personalized management by a multidisciplinary team. The aim of this retrospective multicentric study was to characterize real-world healthcare resource use and patient care for R/M HNSCC in Portugal during the first year after diagnosis. A total of 377 patients ineligible for curative treatment were included, mostly male (92.8%), aged 50-69 years (74.5%), with heavy alcohol (72.7%) or smoking habits (89.3%). Oropharynx (33.2%) and oral cavity (28.7%) were primary tumor locations, with lung metastases being the most common (61.4%). Eligible patients for systemic treatment with palliative intent (80.6%) received up to four treatment lines, with varied regimens. Platinum-based combination chemotherapy dominated first-line treatment (>70%), while single-agent chemotherapy and anti-PD1 immunotherapy were prevalent in later lines. Treatment approaches were uniform across disease stages and primary tumor locations but varied geographically. Treated patients received more multidisciplinary support than those who were ineligible. This study provides the first Portuguese real-world description of R/M HNSCC patient characteristics, treatment patterns, and supportive care during the year after diagnosis, highlighting population heterogeneity and aiming to improve patient management.
引用
收藏
页码:4270 / 4283
页数:14
相关论文
共 50 条
  • [31] A REAL-WORLD OUTCOME RESEARCH STUDY ON QUALITY OF LIFE, WORK PRODUCTIVITY AND HEALTHCARE RESOURCE UTILIZATION IN METASTATIC BREAST CANCER FOR PATIENTS AND CAREGIVERS
    Lambert-Obry, V
    Laliberte, Gouault
    Castonguay, A.
    Zanotti, G.
    Banerjee, R.
    Mates, M.
    Lemieux, J.
    Chabot, P.
    Prady, C.
    Couture, F.
    Lachaine, J.
    VALUE IN HEALTH, 2016, 19 (07) : A616 - A616
  • [32] Anlotinib reversed resistance to PD-1 inhibitors in recurrent and metastatic head and neck cancers: a real-world retrospective study
    Jiang, Jianyun
    Wu, Bin
    Sun, Ying
    Xiang, Jun
    Shen, Chunying
    He, Xiayun
    Ying, Hongmei
    Xia, Zuguang
    CANCER IMMUNOLOGY IMMUNOTHERAPY, 2024, 73 (10)
  • [33] Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
    Gomez-Ulloa, David
    Amonkar, Mayur
    Kothari, Smita
    Cheung, Winson Y.
    Chau, Ian
    Zalcberg, John R.
    Lara Surinach, Nuria
    Falcone, Alfredo
    BMC GASTROENTEROLOGY, 2020, 20 (01)
  • [34] Real-world treatment patterns, healthcare resource use and clinical outcomes of patients receiving second line therapy for advanced or metastatic gastric cancer
    David Gómez-Ulloa
    Mayur Amonkar
    Smita Kothari
    Winson Y. Cheung
    Ian Chau
    John R. Zalcberg
    Núria Lara Suriñach
    Alfredo Falcone
    BMC Gastroenterology, 20
  • [35] Real-world outcomes and healthcare resource utilization in recurrent or advanced endometrial cancer patients rechallenged with platinum chemotherapy in Europe
    Marth, Christian
    Prabhu, Vimalanand
    Kelkar, Sneha
    Zhang, Jingchuan
    Ogando, Yoscar
    GYNECOLOGIC ONCOLOGY, 2023, 176 : S51 - S52
  • [36] Real-world analysis of usage and efficacy of immune check point inhibitors in recurrent/metastatic head and neck cancers
    Domadia, K. R.
    Pandya, N.
    Mandlik, D.
    Patel, D.
    Jani, K.
    Patel, P.
    Patel, P. D.
    Batham, S.
    Hirapara, P. H.
    Modi, V. K.
    Joshipura, A.
    Sharma, N.
    Shah, A.
    Gandhi, M.
    Toprani, D.
    Toprani, R.
    Patel, K.
    ANNALS OF ONCOLOGY, 2024, 35
  • [37] Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy
    Navari, Rudolph M.
    Nelson, Winnie W.
    Shoaib, Sofia
    Singh, Risho
    Zhang, Weiping
    Bailey, William L.
    ADVANCES IN THERAPY, 2023, 40 (07) : 3217 - 3226
  • [38] Real-World Treatment Outcomes, Healthcare Resource Use, and Costs Associated with Antiemetics Among Cancer Patients on Cisplatin-Based Chemotherapy
    Rudolph M. Navari
    Winnie W. Nelson
    Sofia Shoaib
    Risho Singh
    Weiping Zhang
    William L. Bailey
    Advances in Therapy, 2023, 40 : 3217 - 3226
  • [39] Real-world data for immune checkpoint inhibitor therapy as first line treatment of recurrent or metastatic squamous cell cancer of the head and neck
    Wagner, S. M.
    Magnes, T.
    Minichsdorfer, C.
    Gamerith, G.
    Pall, G.
    Greil, R.
    Melchardt, T.
    Fuereder, T.
    ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (SUPPL 4) : 132 - 133
  • [40] Real-world evaluation of nivolumab in patients with non-nasopharyngeal recurrent or metastatic head and neck cancer: A retrospective multi-center study by the Turkish Oncology Group (TOG).
    Akyildiz, Arif
    Guven, Deniz Can
    Koksal, Baris
    Karaoglan, Beliz Bahar
    Salim, Derya Kivrak
    Sutcuoglu, Osman
    Erciyestepe, Mert
    Alan, Ozkan
    Taban, Hakan
    Yildirim, Nilgun
    Sakalar, Teoman
    Yazilitas, Dogan
    Ismayilov, Rashad
    On, Sercan
    Aslan, Ferit
    Demirci, Nebi Serkan
    Kemal, Yasemin
    Diker, Omer
    Gullu, Ibrahim Halil
    Aksoy, Sercan
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)